Prostate Cancer Imaging with Novel PET Tracers.
Curr Urol Rep
; 17(3): 18, 2016 Mar.
Article
in En
| MEDLINE
| ID: mdl-26874530
ABSTRACT
Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Positron-Emission Tomography
Limits:
Humans
/
Male
Language:
En
Journal:
Curr Urol Rep
Journal subject:
UROLOGIA
Year:
2016
Type:
Article
Affiliation country:
United States